KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $3.0 billion.

  • Amgen's Cost of Revenue fell 437.02% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.0 billion, marking a year-over-year decrease of 638.51%. This contributed to the annual value of $12.0 billion for FY2025, which is 638.51% down from last year.
  • As of Q4 2025, Amgen's Cost of Revenue stood at $3.0 billion, which was down 437.02% from $3.1 billion recorded in Q3 2025.
  • Over the past 5 years, Amgen's Cost of Revenue peaked at $3.3 billion during Q3 2024, and registered a low of $1.5 billion during Q1 2021.
  • In the last 5 years, Amgen's Cost of Revenue had a median value of $1.8 billion in 2023 and averaged $2.3 billion.
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 775.81% in 2022, then skyrocketed by 8604.65% in 2024.
  • Over the past 5 years, Amgen's Cost of Revenue (Quarter) stood at $1.7 billion in 2021, then grew by 1.69% to $1.7 billion in 2022, then soared by 78.13% to $3.1 billion in 2023, then changed by 0.0% to $3.1 billion in 2024, then dropped by 4.37% to $3.0 billion in 2025.
  • Its Cost of Revenue was $3.0 billion in Q4 2025, compared to $3.1 billion in Q3 2025 and $3.0 billion in Q2 2025.